1-2-4-trioxane and Schistosomiasis-haematobia

1-2-4-trioxane has been researched along with Schistosomiasis-haematobia* in 1 studies

Other Studies

1 other study(ies) available for 1-2-4-trioxane and Schistosomiasis-haematobia

Article	Year
In vivo activity of aryl ozonides against Schistosoma species. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:2 We evaluated the in vivo antischistosomal activities of 11 structurally diverse synthetic peroxides. Of all compounds tested, ozonide (1,2,4-trioxolane) OZ418 had the highest activity against adult Schistosoma mansoni, with total and female worm burden reductions of 80 and 90% (P < 0.05), respectively. Furthermore, treatment of S. haematobium-infected mice with OZ418 reduced the total worm burden by 86%. In conclusion, OZ418 is a promising antischistosomal lead compound. Topics: Animals; Anthelmintics; Female; Heterocyclic Compounds; Mice; Schistosoma haematobium; Schistosoma mansoni; Schistosomiasis haematobia; Schistosomiasis mansoni; Treatment Outcome	2012

Article

Year

In vivo activity of aryl ozonides against Schistosoma species.

Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:2

We evaluated the in vivo antischistosomal activities of 11 structurally diverse synthetic peroxides. Of all compounds tested, ozonide (1,2,4-trioxolane) OZ418 had the highest activity against adult Schistosoma mansoni, with total and female worm burden reductions of 80 and 90% (P < 0.05), respectively. Furthermore, treatment of S. haematobium-infected mice with OZ418 reduced the total worm burden by 86%. In conclusion, OZ418 is a promising antischistosomal lead compound.

Topics: Animals; Anthelmintics; Female; Heterocyclic Compounds; Mice; Schistosoma haematobium; Schistosoma mansoni; Schistosomiasis haematobia; Schistosomiasis mansoni; Treatment Outcome

2012